Hennion & Walsh Asset Management, Inc. Pacira Bio Sciences, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.89 Billion
- Q2 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 35,450 shares of PCRX stock, worth $464,395. This represents 0.05% of its overall portfolio holdings.
Number of Shares
35,450Holding current value
$464,395% of portfolio
0.05%Shares
5 transactions
Others Institutions Holding PCRX
# of Institutions
301Shares Held
51.5MCall Options Held
378KPut Options Held
1.53M-
Black Rock Inc. New York, NY8.01MShares$105 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$66.6 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.16MShares$28.3 Million0.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.07MShares$27.1 Million0.1% of portfolio
-
State Street Corp Boston, MA1.9MShares$24.9 Million0.0% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $600M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...